# of Displayed Technologies: 2 / 2


Oncolytic Virus Limiting Tumor Progression And Improving Viral Replication
TS-037508 — An engineered oncolytic virus sequestering the ligand for receptor for advanced glycation end products (RAGE) signaling, resulting in improved viral replication and reduction of tumor progression.
The multi ligand receptor for advanced glycation end products (RAGE) of the immunoglobulin superfamily is expressed on multiple cell types that are part of the immune-inflammatory response. These receptors propagate cellular dysfunction in several disorders such as in tumors and diabetes. RAGE is …
  • College: College of Medicine (COM)
  • Inventors: Kaur, Balveen
  • Licensing Officer: Davis, Stewart

Oncolytic Virus Expressing Angiostatic Factors under an Immediate Early Viral Promoter
TS-015264 — Tumor-targeting oncolytic virus is able to kill cancer cells while sparing normal cells and encodes anti-angiogenic factors that reduced blood vessel formation and may modulate innate immune response.
Glioblastoma is the most common primary malignant brain tumor, with a median survival of less than 15 months from diagnosis. Current standard of care combines surgical resection, with radiation and chemotherapy. However, many patients recur with resistant tumors that require alternative treatments…
  • College: College of Medicine (COM)
  • Inventors: Kaur, Balveen; Chiocca, Ennio; Saeki, Yoshinaga
  • Licensing Officer: Davis, Stewart

Loading icon